{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"119"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks as their best response. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (MR was determined using European Group for Blood and Marrow Transplantation criteria)","groups":[{"description":"Best Supportive Care: Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).\n\nOptional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle).","id":"OG000","title":"Best Supportive Care"},{"description":"Carfilzomib: 20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days \\[Days 1, 2, 8, 9, 15, 16\\] for individual subjects).","id":"OG001","title":"Carfilzomib"}],"paramType":"NUMBER","populationDescription":"The intent to treat (ITT) analysis set comprised all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization through the final analysis data cutoff with longest follow-up time of approximately 31 months. Median follow up times were 26.6 months and 23.1 months for Carfilzomib and Best Supportive Care groups, respectively.","title":"Disease Control","type":"SECONDARY","unitOfMeasure":"participants"}